07/06/2005 WABDELR1 00000050 081641 10006856

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:)	Examiner: McKelvey, Terry Alan
Kevin P. BAKER, et al.)	Art Unit: 1636
,)	1200 1000
Application Serial No. 10/006,856)	Confirmation No: 8365
Filed: December 6, 2001)	Attorney's Docket No. 39780-2830 P1C14
For: SECRETED AND)	Customer No. 35489
TRANSMEMBRANE)	
POLYPEPTIDES AND NUCLEIC)	
ACIDS ENCODING THE SAME)	

EXPRESS MAIL LABEL NO.: EL 976 545 064 US

DATE MAILED: JUNE 29, 2005

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

MAIL STOP AMENDMENT

Commissioner for Patents PO Box 1450 Alexandria, Virginia 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form Supplemental PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

This state	ment qu	alifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):
	(1)	It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d) OR
	(2)	It is being filed within 3 months of entry of a national stage
	(3)	It is being filed before the mail date of the first Office Action on the merits

-- OR --

	-	filed before the mailing of a first Office continued examination under § 1.114		
37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Of action on the merits, but before the mailing date of the earlier of a final office action under §1 or a notice of allowance under §1.311, then:				
	a certification as sp	pecified in §1.97(e) is provided below;	or	
		s set forth in §1.17(p) is authorized belier papers filed together with this states		
office a	$7 C.F.R. \ \S 1.97(d)$. If this statement is being filed after the mailing date of the earlier of a final fice action under $\S 1.113$ or a notice of allowance under $\S 1.311$, but before payment of the issue e, then:			
A.	a certification as sp	pecified in §1.97(e) is completed below	v; and	
B.	a petition under 37 submitted herewith	C.F.R. §1.97(d) requesting considerate; and	ion of this statement is	
C.		s set forth in §1.17(i)(1) is authorized been papers filed together with this states		
of \$180	00 and charge any	ommissioner is hereby authorized to chadditional fees or credit any overpaym Account No. <u>08-1641 (Attorney's Do</u>	nent associated with this	

Respectfully submitted,

Dated: June 28, 2005

By: Bonnie Sum Barrie D. Greene (Reg. No. 46,740)

HELLER EHRMAN WHITE & McAULIFFE LLP

275 Middlefield Road

Menlo Park, CA 94025-3506 Telephone: (650) 324-7000 Facsimile: (650) 324-0638

SV 2131171 v1 (39780.2830)

Form PTO-1449 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		Attorney's Docket No. 39780-2830 P1C14 Application Serial No. 10/006,856						
		Applicant(s)						
) INTORM	ATION	DISCLOS	OKE STATEMENT	Kevin P. B.	AKER.	et al.		
				Filing Date:		oup Art Uni	t:	
	use sev	eral sheets i	f necessary)	December 6, 2001		1636		
			U.S.	PATENT DOCUMENTS				
Examiner	Ref.	Date	Document No.	Name	Class	Subclass	Filing Date	
Initials	No.						(if appropr	iate)
		No.	S. 14 S. C. O. W. M					
	Earl 1		and the second s	GN PATENT DOCUMENTS				val. 4
Examiner	Ref.	Date	Document No.	Name	Class	Subclass		
Initials	No.						YES	NO
		Later Harris III	Degrada zango ugrassu urangsugssaga ugaa akabings	The state of the s	Viewes - November	s. 10. 5. 21 1 8 9 1 a. 2 1 1		
			그 본통 회사에 대통령을 하는 선택하다 되었다. 경기를 되어야 하지만 가능했습니다.	THER DOCUMENTS				
Examiner	Ref.	Title	(incluaing au	thor, title, date, pertinent pages, etc.)				jalan kalan sa
Initials	No.	Title						
	1.	Goldwaser,	Itzhak, et al., "L-Glutar	nic Acid γ-Monohydroxamate", The Jour	nal of B	iomedical Cl	nemistry. Vo	1. 274.
		No. 37, pp	26617-26624, Septembe	er 10, 1999.			•	
	2.		, et al., "HER-2/neu Bre	eat Cancer Predictive Testing", Oathology	Associa	ates Medical	Laboratores	_
		(1999).						
	3.			Amplification on Gene Expression Patter	ns in Br	east Cancer ¹	² ", Cancer	
		<i>Research</i> – <u>62</u> :6240-6245 (2002).						
	4.	Mueller, Wendy M., et al., "Evidence That Glucose Metabolism Regulates Leptin Secretion from Cultured Rat						
	5.	Adipocytes", Endocrinology, Vol. 139, No. 2, pp 551-558 (1998). Mueller, Wendy M., et al., "Effects of Metformin and Vanadium on Leptin Secretion from Cultured Rat						
	<i>J</i> .			of Metorium and Vanadium on Leptin S	ecretion	i iroiii Cuitui	ed Rat	
	6.			Study of Gene Copy Numbers, Transcrip	ots, and	Protein Leve	ls in Pairs of	Non-
				sitional Cell Carcinomas", Molecular & C				
	7.			nalysis Reveals a Major Direct Role of Di				
		Transcriptional Program of Human Breast Tumors", PNAS – 99(20):12963-12968 (2002).						
	8.			iabetic Agent Pioglitazone Increases Expi				
				ger Ribonucleic Acid Transcript Stability	", Endoc	erinology, Vo	ol. 133, No. 1	l, pp
	9.	352-359 (19		phonoca Differentiation Decal Change II	-4-1	-1 Cl-+ 1 D		
	9.			nhances Differentiation, Basal Glucose U _l y, Vol. 137, No. 11, pp 4706-4712 (1996		na Glut I Pro	itein Leveis i	ın
		313-B17tu	ipocytes, Endocrinolog	,y, voi: 137, tvo: 11, pp +700-4712 (1990)			
			· ·			· - ···		
,		,					· · · · · ·	

EXAMINER: DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d). SV 2131171 v1